mars best practices: valuations in the biotech industry - raymond king
DESCRIPTION
Speaker: Raymond King, Senior Manager, TSX/TSX Venture Exchange Canada's biotechnology and cleantech communities have a history of developing world-leading technologies—but for these industries to grow, they must have access to new capital to fund research and development that will allow Canada to maintain its position as a world leader Part of the MaRS Best Practices Series - More information http://www.marsdd.com/events/details.html?uuid=8211fe27-3ce5-4a7d-b264-4c367fcd6b7fTRANSCRIPT
![Page 1: MaRS Best Practices: Valuations in the biotech Industry - Raymond King](https://reader034.vdocument.in/reader034/viewer/2022051514/5481ee98b079591f0c8b4657/html5/thumbnails/1.jpg)
1
MaRS Best Practices Series
Special Valuation Series Nov. 12th, 2010
MaRS Best Practices Special Valuation Series
Friday Nov 12th @ Noon
Raymond King, Senior Manager Toronto Stock Exchange
Wayne Schnarr, Analyst, Equicom Toronto Stock Exchange
![Page 2: MaRS Best Practices: Valuations in the biotech Industry - Raymond King](https://reader034.vdocument.in/reader034/viewer/2022051514/5481ee98b079591f0c8b4657/html5/thumbnails/2.jpg)
2
A Capital Opportunity for Life Science Companies Listing on Toronto Stock Exchange and TSX Venture Exchange
Raymond D. King, MBA Senior Manager, Global Diversified Industrials
Listings Business Development
![Page 3: MaRS Best Practices: Valuations in the biotech Industry - Raymond King](https://reader034.vdocument.in/reader034/viewer/2022051514/5481ee98b079591f0c8b4657/html5/thumbnails/3.jpg)
3
Who is TMX Group?
Toronto Stock Exchange and TSX Venture Exchange
Life Science Sector
Going Public
Outline
![Page 4: MaRS Best Practices: Valuations in the biotech Industry - Raymond King](https://reader034.vdocument.in/reader034/viewer/2022051514/5481ee98b079591f0c8b4657/html5/thumbnails/4.jpg)
4
7th largest exchange group By domestic market cap1
1st in North America
2ndglobally
By number of issuers1
TMX Group - Global Leader in Equities
6th largest exchange group By equity capital raised2
1Issuers on TSX and TSXV (WFE, June 2010) 2(WFE and Capital IQ, Dec 2009)
![Page 5: MaRS Best Practices: Valuations in the biotech Industry - Raymond King](https://reader034.vdocument.in/reader034/viewer/2022051514/5481ee98b079591f0c8b4657/html5/thumbnails/5.jpg)
5
North American Equity Stock Market Continuum
OTC - Pink Sheets
OTCBB
NASDAQ
NYSE
• Minimal/No listing standards
• Senior listing standards
• Disclosure rules • Junior listing
standards
CNSX
![Page 6: MaRS Best Practices: Valuations in the biotech Industry - Raymond King](https://reader034.vdocument.in/reader034/viewer/2022051514/5481ee98b079591f0c8b4657/html5/thumbnails/6.jpg)
6
2,177 companies 20 graduates in First Half 2010 20 graduates in 2009 45 graduates in 2008
1,488 companies
TSX Venture Exchange
• Access to capital for earlier stage companies or smaller financings
• Total market cap of $38 Billion & average market cap of $17.4MM
• Cost effective stepping stone for international companies looking to list on a quality North American market
• Exchange mandate to mentor management of newly public companies
• Streamlined graduation to TSX when senior market requirements are met
• 103 year history
Toronto Stock Exchange
• Senior market for well established businesses and management teams with experience in public markets
• Total market cap of $1.8 Trillion & average market cap of $1.2B
• 30% of TSX issuers >$500M are interlisted on a US exchange
• Access to larger, more international institutional investors and greater analyst coverage
• Globally visible specialized indices
• 157 year history
Unique Equity Market Structure
![Page 7: MaRS Best Practices: Valuations in the biotech Industry - Raymond King](https://reader034.vdocument.in/reader034/viewer/2022051514/5481ee98b079591f0c8b4657/html5/thumbnails/7.jpg)
7
TMX Group Serves Companies at all Stages of Growth
Market Capitalization Toronto Stock Exchange and TSX Venture Exchange
Unique feeder system
471 graduates + 85 M&A*
*From January 1, 2000 – June 30, 2010
7
Toronto Stock Exchange issuer base: 1,488 issuers, ~$1.8 trillion market cap TSX Venture Exchange issuer base (excludes NEX): 2,177 issuers, ~$37.7 billion market cap
As at June 30, 2010
514 Issuers
498 Issuers
476 Issuers
2016 Issuers 142
19 Issuers
![Page 8: MaRS Best Practices: Valuations in the biotech Industry - Raymond King](https://reader034.vdocument.in/reader034/viewer/2022051514/5481ee98b079591f0c8b4657/html5/thumbnails/8.jpg)
8
International Investment Community Trades on Toronto Stock Exchange
25 International Brokers including: Barclays Capital Citigroup CSFB Deutsche Bank Goldman Sachs HSBC JP Morgan Macquarie Capital Markets Merrill Lynch Morgan Stanley Raymond James Thomas Weisel State Street UBS
80 Canadian Brokers including: BMO Nesbitt Burns Canaccord Genuity CIBC World Markets GMP Securities RBC DS Scotia Capital Markets TD Securities National Bank Financial
~35% of daily trading originates from International brokers
Volume CAGR 14%
Transactions CAGR 37%
Toronto Stock Exchange Volume and Transactions (2004-2009)
![Page 9: MaRS Best Practices: Valuations in the biotech Industry - Raymond King](https://reader034.vdocument.in/reader034/viewer/2022051514/5481ee98b079591f0c8b4657/html5/thumbnails/9.jpg)
9
Who is TMX Group?
Toronto Stock Exchange and TSX Venture Exchange
Life Science Sector
Going Public
Outline
![Page 10: MaRS Best Practices: Valuations in the biotech Industry - Raymond King](https://reader034.vdocument.in/reader034/viewer/2022051514/5481ee98b079591f0c8b4657/html5/thumbnails/10.jpg)
10
TMX Group’s Equity Exchanges Support a Diverse Issuer Base
Number of Issuers by Sector
Includes issuers on Toronto Stock Exchange and TSX Venture Exchange (100% = 3665)
As at June 30 2010
![Page 11: MaRS Best Practices: Valuations in the biotech Industry - Raymond King](https://reader034.vdocument.in/reader034/viewer/2022051514/5481ee98b079591f0c8b4657/html5/thumbnails/11.jpg)
11
Why Companies Consider TSX and TSX Venture Exchange
Unique Public Market for small to mid cap companies
• Access to Capital
• Liquidity
• Visibility
![Page 12: MaRS Best Practices: Valuations in the biotech Industry - Raymond King](https://reader034.vdocument.in/reader034/viewer/2022051514/5481ee98b079591f0c8b4657/html5/thumbnails/12.jpg)
12
Access to Capital: 2009 was a record year for financing on TMX Group Equity Exchanges
*NOTE: TSX Venture Exchange commenced operations on November 29 1999
Toronto Stock Exchange and TSX Venture Exchange Total Financings (C$Billions) 1999 – 2010 August
![Page 13: MaRS Best Practices: Valuations in the biotech Industry - Raymond King](https://reader034.vdocument.in/reader034/viewer/2022051514/5481ee98b079591f0c8b4657/html5/thumbnails/13.jpg)
13
TSX and TSX Venture Exchange have shown consistent growth in liquidity
Billions of Shares
Toronto Stock Exchange Volume of Shares Traded
Billions of Shares
TSX Venture Exchange Volume of Shares Traded
![Page 14: MaRS Best Practices: Valuations in the biotech Industry - Raymond King](https://reader034.vdocument.in/reader034/viewer/2022051514/5481ee98b079591f0c8b4657/html5/thumbnails/14.jpg)
14
TMX Group Listing can Provide Analyst Visibility
872 TSX Companies get Analyst Coverage
Source: Capital IQ, December 31 2009
4 Average Number of Analysts Covering
TSX Cos.
259 TSXV Companies get
Analyst Coverage
![Page 15: MaRS Best Practices: Valuations in the biotech Industry - Raymond King](https://reader034.vdocument.in/reader034/viewer/2022051514/5481ee98b079591f0c8b4657/html5/thumbnails/15.jpg)
15
Who is TMX Group?
Toronto Stock Exchange and TSX Venture Exchange
Life Science Sector
Going Public
Outline
![Page 16: MaRS Best Practices: Valuations in the biotech Industry - Raymond King](https://reader034.vdocument.in/reader034/viewer/2022051514/5481ee98b079591f0c8b4657/html5/thumbnails/16.jpg)
16
Life Sciences Companies By The Numbers
136 Life Sciences Cos.
$11B Market Cap
$367M Raised Through 84
Financings
4B Shares Traded
Through 2.4Million Transactions
Average Number of Analysts Covering Life Sciences Cos:3
7 New Life Sciences
Listings
YTD Dec 31 2009 Analyst Coverage Source: Capital IQ
![Page 17: MaRS Best Practices: Valuations in the biotech Industry - Raymond King](https://reader034.vdocument.in/reader034/viewer/2022051514/5481ee98b079591f0c8b4657/html5/thumbnails/17.jpg)
17
Who is TMX Group?
Toronto Stock Exchange and TSX Venture Exchange
Life Science Sector
Going Public
Outline
![Page 18: MaRS Best Practices: Valuations in the biotech Industry - Raymond King](https://reader034.vdocument.in/reader034/viewer/2022051514/5481ee98b079591f0c8b4657/html5/thumbnails/18.jpg)
18
Benefits of Going Public
![Page 19: MaRS Best Practices: Valuations in the biotech Industry - Raymond King](https://reader034.vdocument.in/reader034/viewer/2022051514/5481ee98b079591f0c8b4657/html5/thumbnails/19.jpg)
19
Methods for Going Public on Toronto Stock Exchange or TSX Venture Exchange
![Page 20: MaRS Best Practices: Valuations in the biotech Industry - Raymond King](https://reader034.vdocument.in/reader034/viewer/2022051514/5481ee98b079591f0c8b4657/html5/thumbnails/20.jpg)
20
• IPO market window closed
• Listing certainty needed – removes underwriting risk
• Financing amount below a minimum IPO floor
• Lower up-front costs
• A private placement can be escrowed until reverse merger completed
When to Pursue an IPO vs. a CPC™ Transaction
CPC™ IPO
• Demand for primary distribution
• Scale and liquidity criteria met
• Limited transaction timeline constraints
• Sufficient capital to fund up-front costs
![Page 21: MaRS Best Practices: Valuations in the biotech Industry - Raymond King](https://reader034.vdocument.in/reader034/viewer/2022051514/5481ee98b079591f0c8b4657/html5/thumbnails/21.jpg)
21
Capital Pool Company™ (CPC) Program has a Strong Track Record
Since inception in 1987: • Over 2095 CPCs have been created • 80% have completed their QT – over 1660 companies
• 332 Graduates now trade on TSX • 96 of the grads were CPCs
As at June 30 2010
![Page 22: MaRS Best Practices: Valuations in the biotech Industry - Raymond King](https://reader034.vdocument.in/reader034/viewer/2022051514/5481ee98b079591f0c8b4657/html5/thumbnails/22.jpg)
22 22
CPC Acquires Business (QT)
Public Financing and CPC Trades
Seed 24 Months Maximum
Capital Pool Company: Process
Aftermarket and Growth
![Page 23: MaRS Best Practices: Valuations in the biotech Industry - Raymond King](https://reader034.vdocument.in/reader034/viewer/2022051514/5481ee98b079591f0c8b4657/html5/thumbnails/23.jpg)
23 23
Seed Financing • seed financing of the company by 3-5 Founders/Directors
CPC IPO • a prospectus offering to create a corporate vehicle with public
distribution
Qualifying Transaction (QT) • a target business is identified, disclosed and acquired
Aftermarket and Growth • company trades and executes its business plan
Capital Pool Company: Milestones
![Page 24: MaRS Best Practices: Valuations in the biotech Industry - Raymond King](https://reader034.vdocument.in/reader034/viewer/2022051514/5481ee98b079591f0c8b4657/html5/thumbnails/24.jpg)
24 24
CPC Acquires Business (QT)
Public Financing and CPC Trades Seed
24 Months Maximum
Qualifying Transaction
![Page 25: MaRS Best Practices: Valuations in the biotech Industry - Raymond King](https://reader034.vdocument.in/reader034/viewer/2022051514/5481ee98b079591f0c8b4657/html5/thumbnails/25.jpg)
25 25
Considerations for a Qualifying Transaction:
• Significant growth opportunity & reason to be public
• Strong & coachable management
• Capital needs: $5+ Million
• Close to or at commercialization
• Meets minimum listing and audit requirements
• Stock options and acquisition currency
• Strong market appetite
• 12 to 18 month cash requirements (can be financed)
Selecting a QT Candidate
![Page 26: MaRS Best Practices: Valuations in the biotech Industry - Raymond King](https://reader034.vdocument.in/reader034/viewer/2022051514/5481ee98b079591f0c8b4657/html5/thumbnails/26.jpg)
26 26
Consider this…
Success Factors:
• Lots of cash on closing
• Market interest and understanding
• Deliver in short term post closing
• Reasonable valuation – not always maximum valuation
Potential Pitfalls:
• Listing requirements shortfalls
• Insufficient cash/working capital on closing
• Valuation versus escrow regime (TSXV Policy 5.4)
• PIFs - timing and impact on circular
![Page 27: MaRS Best Practices: Valuations in the biotech Industry - Raymond King](https://reader034.vdocument.in/reader034/viewer/2022051514/5481ee98b079591f0c8b4657/html5/thumbnails/27.jpg)
27 27
CPC Acquires Business (QT)
Public Financing and CPC Trades Seed
24 Months Maximum
Aftermarket and Growth
Aftermarket and Growth
![Page 28: MaRS Best Practices: Valuations in the biotech Industry - Raymond King](https://reader034.vdocument.in/reader034/viewer/2022051514/5481ee98b079591f0c8b4657/html5/thumbnails/28.jpg)
28 28
Consider this…
Success Factors:
• Press release clarity / quality
• Broker management and support
• Timely disclosure against published milestones (good and bad)
Potential Pitfalls:
• Orphan status
• Mistrust of management’s willingness to communicate
• Market fluctuations
![Page 29: MaRS Best Practices: Valuations in the biotech Industry - Raymond King](https://reader034.vdocument.in/reader034/viewer/2022051514/5481ee98b079591f0c8b4657/html5/thumbnails/29.jpg)
29
Listing Requirements – Life Sciences
TSX Venture Exchange Toronto Stock Exchange
Tier 1 Tier 2
Net Tangible Assets, Revenue or Financing
$5 million NTA OR $5 million revenue
$750,000 NTA OR $500,000 revenue OR $2 million arm’s length financing
Adequate Working Capital Adequate for 18 months plus $200,000 unallocated funds
Adequate for 12 months plus $100,000 unallocated funds
Funds to cover all R&D and capital expenditures for 2 years
Cash in Treasury Minimum $12 million raised via prospectus offering
History History of operations or validation of business Minimum 2 year history of R&D activities
Distribution • Public float of 1 million shares • 250 board lot shareholders • 20% of issued and outstanding
shares in hands of public shareholders
• Public float of 500,000 shares • 200 board lot shareholders • 20% of issued and outstanding
shares in hands of public shareholders
• 1 million free trading public shares
• $4 million held by public • 300 public board lot
shareholders
Sponsorship Generally required
![Page 30: MaRS Best Practices: Valuations in the biotech Industry - Raymond King](https://reader034.vdocument.in/reader034/viewer/2022051514/5481ee98b079591f0c8b4657/html5/thumbnails/30.jpg)
30
Disclaimer
This document is for information purposes only and is not an invitation to purchase securities listed on Toronto Stock Exchange and/or TSX Venture Exchange or Natural Gas Exchange. TMX Group Inc. and its affiliates do not endorse or recommend any securities referenced in this document. Please seek professional advice to evaluate specific securities. While the information herein is collected and compiled with care, neither TMX Group Inc. nor any of its affiliated companies represents, warrants or guarantees the accuracy or the completeness of the information. You agree not to rely on the information contained herein for any trading, business or financial purpose. This information is provided with the express condition, to which by making use thereof you expressly consent, that no liability shall be incurred by TMX Group Inc. and/or any of its affiliates as a result of any errors or inaccuracies herein or any use or reliance upon this information. © 2010 TMX Group Inc.
Diversified Industrials Raymond King 416 947-4675 [email protected]